Alzamend Neuro (ALZN) Stock Chart & Stock Price History $3.55 +0.03 (+0.85%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alzamend Neuro Stock Price Performance The Alzamend Neuro (ALZN) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 93.64%, with a year-to-date return of -66.00%. In the past month, the stock has decreased 42.83%, reflecting recent market activity. As of the latest close, Alzamend Neuro traded at $3.52 with a market cap of $2.82 million and volume of 43,905 shares. Receive ALZN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.41%1 Month Performance-42.83%3 Month Performance-58.81%Year-To-Date Performance-66.00%1 Year Performance-93.64% ALZN Stock Chart for Thursday, May, 22, 2025 ALZN Chart by TradingView Alzamend Neuro Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization05/21/2025$3.52$3.52$3.55$3.4543,905 shs$2.82 million05/20/2025$3.60$3.52-2.22%$3.60$3.3485,176 shs$2.82 million05/19/2025$3.40$3.60+5.88%$3.66$3.31167,490 shs$2.88 million05/16/2025$3.29$3.40+3.34%$3.48$3.06123,095 shs$2.72 million05/15/2025$3.85$3.29-14.55%$3.83$3.16173,165 shs$23.72 million05/14/2025$4.18$3.85-7.89%$4.07$3.83237,643 shs$27.76 million05/13/2025$5.15$4.18-18.83%$6.12$3.945.77 million shs$30.13 million05/12/2025$5.92$5.15-13.05%$5.79$5.03159,478 shs$37.13 million05/09/2025$4.86$5.92+21.87%$5.94$4.6835,575 shs$4.35 million05/08/2025$5.31$4.86-8.47%$5.08$4.5953,032 shs$3.57 million Get the Latest News and Ratings for ALZN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. 05/07/2025$5.72$5.31-7.16%$6.10$4.96106,858 shs$3.90 million05/06/2025$6.12$5.72-6.54%$6.29$5.6917,196 shs$4.20 million05/05/2025$6.03$6.12+1.49%$6.48$5.9311,994 shs$4.49 million05/02/2025$5.99$6.03+0.74%$6.33$5.649,991 shs$4.43 million05/01/2025$5.94$5.99+0.77%$6.12$5.9413,299 shs$4.40 million04/30/2025$5.98$5.94-0.69%$6.17$5.927,253 shs$4.36 million04/29/2025$5.96$5.98+0.39%$6.21$5.945,687 shs$4.39 million04/28/2025$6.12$5.96-2.65%$6.12$5.8115,153 shs$4.38 million04/25/2025$6.31$6.12-2.94%$6.44$6.085,889 shs$4.49 million04/24/2025$6.17$6.31+2.26%$6.31$5.8613,588 shs$4.63 million04/23/2025$6.21$6.17-0.71%$6.39$6.048,972 shs$4.53 million04/22/2025$6.11$6.21+1.56%$6.37$6.1210,382 shs$4.56 million04/21/2025$6.03$6.11+1.40%$6.33$6.039,343 shs$4.49 million Related Companies Hoth Therapeutics Stock Chart Lakeshore Biopharma Stock Chart BioCardia Stock Chart BioLineRx Stock Chart Dogwood Therapeutics Stock Chart PHAXIAM Therapeutics Stock Chart Athira Pharma Stock Chart Talphera Stock Chart Cyclerion Therapeutics Stock Chart Aprea Therapeutics Stock Chart Receive ALZN Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Alzamend Neuro and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ALZN) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
